Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRXBiotechnology
-$0.05 today
- Market cap
- $792.52M
- Beta
- 1.07
- P/E (TTM)
- -30.5
- EPS (TTM)
- -$0.07
Volume 2.42M
Average 2.48M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
Intrinsic Alpha fair value
Locked
Current Price
$1.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +610.3% | +39.1% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +610.3% over three years. Forward estimates point to Revenue at +39.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
PTC Therapeutics, Inc. NASDAQ:PTCT | $5.30B | $63.49 | Undervalued | -35.0 | -21.29% |
Ionis Pharmaceuticals, Inc. NASDAQ:IONS | $4.84B | $29.06 | Not rated | -37.5 | -63.81% |
BioCryst Pharmaceuticals, Inc. NASDAQ:BCRX | $1.96B | $7.61 | Undervalued | -4.8 | +7.14% |
Trevi Therapeutics, Inc. NASDAQ:TRVI | $1.95B | $13.65 | Not rated | -53.6 | +19.45% |
MannKind Corporation NASDAQ:MNKD | $1.33B | $4.13 | Overvalued | -50.3 | -19.57% |
Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | $837.18M | $44.46 | Undervalued | 1.7 | -7.14% |
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | $814.71M | $7.86 | Not rated | -6.7 | -32.77% |
Ovid Therapeutics Inc. NASDAQ:OVID | $479.38M | $2.54 | Not rated | -7.1 | +68.18% |
DiaMedica Therapeutics Inc. NASDAQ:DMAC | $474.01M | $8.79 | Not rated | -8.8 | +21.45% |
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | $80.59M | $0.43 | Not rated | -1.2 | -87.42% |
Continue the stock analysis
Jump to another research area for this company.